Vote Scores

Home / Companies / Xeris Biopharma Holdings, Inc. / 4 Jun 2026

Meeting · year to 30 June 2026300 filers reporting

Xeris Biopharma Holdings, Inc.: meeting of 4 Jun 2026

Votes reported on Form N-PX, item by item

300 Form N-PX filers reported votes at the Xeris Biopharma Holdings, Inc. meeting of 4 Jun 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

2 nominees; 46.9% of reported votes for; 70 filers withheld from or voted against at least one nominee.

345 vote records from 93 filers. 37 of the 93 filers that marked the item either way voted against management.

30.1% for0.0% against69.9% other39.8% against management93 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

426 vote records from 298 filers. 22 of the 287 filers that marked the item either way voted against management. 11 filers reported this item without a management mark.

88.3% for7.4% against4.4% other7.7% against management298 filers95.7% for4.2% against0.0% other4.2% against management83,805,588 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

174 vote records from 94 filers. 0 of the 94 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management94 filers100.0% for0.0% against0.0% other0.0% against management30,371,448 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesSplit or no voteForFor
FidelityForForFor
DimensionalAbstain or withhold *ForFor
State Street and SPDRAbstain or withhold *ForFor
American CenturyAbstain or withhold *Against *For
Franklin TempletonForForFor
InvescoSplit or no voteAgainst *For
EquitableAbstain or withhold *ForFor
Charles SchwabSplit or no voteForFor
Nuveen and TIAAForForFor
ProShares and ProFundsAbstain or withhold *ForFor
John Hancock and ManulifeAbstain or withhold *ForFor
Morgan Stanley, Eaton Vance and CalvertAbstain or withhold *ForFor
J.P. MorganNo reportForNo report
Goldman SachsForForFor
PGIM and PrudentialNo reportForNo report
Jackson National fundsAbstain or withhold *ForFor
Northern Trust and FlexSharesForForFor
SEISplit or no voteForFor
T. Rowe PriceSplit or no voteForFor
Lincoln FinancialAbstain or withholdForFor
VoyaAbstain or withhold *ForFor
First TrustAbstain or withhold *ForFor
Russell InvestmentsSplit or no voteForFor
NationwideSplit or no voteForFor
Victory CapitalAbstain or withhold *ForFor
Brighthouse FundsAbstain or withholdForFor
Guggenheim and RydexAbstain or withhold *ForFor
Columbia ThreadneedleForForFor
BNY MellonNo reportAgainst *No report
PrincipalAbstain or withhold *ForFor
Pacific Life fundsSplit or no voteForFor
Global XSplit or no voteForFor
Federated HermesForForFor
AllianceBernsteinNo reportForNo report
DWSAbstain or withhold *ForFor
AllspringNo reportSplit or no voteNo report
MassMutualNo reportForNo report
Harbor FundsAbstain or withhold *ForFor
Janus HendersonAbstain or withhold *ForFor
Neuberger BermanNo reportForNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Xeris Biopharma Holdings, Inc. meeting?

300 Form N-PX filers reported votes at the meeting of 4 Jun 2026. On say-on-pay, 22 of 287 voted against management (7.7%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Xeris Biopharma Holdings, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Xeris Biopharma Holdings, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Xeris Biopharma Holdings, Inc. with a meeting date within three days of 4 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.